Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches

AIDS

Volumn 27, Issue SUIPPL.1, 2013, Pages

  Polis, Chelsea B ^a   Westreich, Daniel ^b,c   Balkus, Jennifer E ^d,e   Heffron, Renee ^e  

^a UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

contraception; depot medroxyprogesterone acetate; HIV acquisition; injectable; observational epidemiology

Indexed keywords

CONTRACEPTIVE AGENT;

ARTICLE; EXPOSURE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASUREMENT ERROR; MEDIATOR; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; RISK;

BIOMEDICAL RESEARCH; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INJECTIONS; RISK ASSESSMENT; UNITED STATES;

EID: 84885585444     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000036     Document Type: Article

References (59)

1. World Health Organization. Hormonal contraception and HIV: technical statement. Geneva, Switzerland; 2012.
2. Morrison CS, Nanda K. Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 2012; 12:2-3.
3. Ahmed S, Li Q, Liu L, Tsui AO. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet 2012; 380:111-125.
4. United Nations Department of Economic and Social Affairs. World contraceptive use, 2011. Available at: www. un. org/esa/ population/ publications/contraceptive2011/contraceptive2011. htm. [Accessed 25 July 2013].
5. Malarcher S, Meirik O, Lebetkin E, Shah I, Spieler J, Stanback J. Provision of DMPA by community health workers: what the evidence shows. Contraception 2011; 83:495-503.
6. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797-808.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
8. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380-382.
9. World Health Organization. GRADE Evidence Profile for hormonal contraception for women at high risk of HIV; 2012. http://www. who. int/reproductivehealth/topics/family-planning/ GRADEprofile-high-risk-HIV. pdf. [Accessed 25 July 2013].
10. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64:401-406.
11. McCoy SI, Zheng W, Montgomery E, Blanchard K, van Der Straten A, de Bryn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in the Methods for Improving Reproductive Health in Africa (MIRA) study. AIDS 2013; 27:1001-1009.
12. Heffron R, Rees H, Mugo N, Baeten J. Authors' reply: use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis 2012; 12:510-511.
13. Smit J, Beksinska M. Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV. J Acquir Immune Defic Syndr 2013; 62:363-365.
14. World Health Organization Department of Reproductive Health and Research (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP) Knowledge for Health Project. Family planning: a global handbook for Providers (2011 update). Baltimore and Geneva; 2011.
15. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166-174.
16. Magwali TL, Steiner MJ, Toms H, Brown JM. How are condoms used in a family planning setting: evidence from Zimbabwe. Cent Afr J Med 2005; 51:79-84.
17. Aklilu M, Messele T, Tsegaye A, Biru T, Mariam DH, van Benthem B, et al. Factors associated with HIV-1 infection among sex workers of Addis Ababa, Ethiopia. AIDS 2001; 15: 87-96.
18. Callegari L, Harper CC, van der Straten A, Kamba M, Chipato T, Padian NS. Consistent condom use in married Zimbabwean women after a condom intervention. Sex Trans Dis 2008; 35: 624-630.
19. Van Rossem R, Meekers D, Akinyemi Z. Consistent condom use with different types of partners: evidence from two Nigerian surveys. AIDS Educ Prev 2001; 13:252-267.
20. Cushman LF, Romero D, Kalmuss D, Davidson AR, Heartwell S, Rulin M. Condom use among women choosing long-term hormonal contraception. Fam Plann Persp 1998; 30:240-243.
21. Sangi-Haghpeykar H, Posner SF, Poindexter AN 3rd. Consistency of condom use among low-income hormonal contraceptive users. Persp Sex Reprod Health 2005; 37:184-191.
22. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.
23. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010; 53:606-613.
24. Morrison CS, Chen P, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778-1781.
25. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 2012; 26:497-504.
26. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
27. Moodie EE, Stephens DA. Using directed acyclic graphs to detect limitations of traditional regression in longitudinal studies. Int J Public Health 2010; 55:701-703.
28. Glymour MM, Greenland S. Causal diagrams. In: Rothman KJ, Greenland S, Lash TL,editors. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp. 183-209.
29. Pearl J. Causality. 2nd ed. New York, NY: Cambridge University Press; 2009.
30. Pearl J. Causal diagrams for empirical research. Biometrika 1995; 82:669.
31. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10:37-48.
32. Joseph KS. Commentary: exegesis of effect modification-biological or spurious? Paediatr Perinat Epidemiol 2009; 23:417-420author reply 421-413.
33. Pearl J. Direct and indirect effects. In: Proceedings of 7th Conference on Uncertainty in Artificial Intelligence. San Francisco, CA; 2001. pp. 411-420.
34. VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. Epidemiology 2009; 20:18-26.
35. Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol 2002; 31:163-165.
36. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011; 2011:1-10.
37. Friend DR. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Exp Opin Drug Delivery 2012; 9:417-427.
38. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27:105-113.
39. Chomont N, Gresenguet G, Levy M, Hocini H, Becquart P, Matta M, et al. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol 2001; 8:955-958.
40. Aho J, Koushik A, Diakite SL, Loua KM, Nguyen VK, Rashed S. Biological validation of self-reported condom use among sex workers in Guinea. AIDS Behav 2010; 14:1287-1293.
41. Phillips AE, Gomez GB, Boily MC, Garnett GP. A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low-and middle-income countries. Int J Epidemiol 2010; 39:1541-1555.
42. Smith JA, Butler AR, Polis CB, Gregson S, Stanton D, Hallett TB. Programmatic implications: balancing maternal mortality and HIV risk; presentation 114. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; 2013.
43. Mugo N, Heffron R, Donnell D, Wald A, Were E O, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011; 25:1887-1895.
44. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366:1182-1188.
45. Westreich D, Cole SR. Invited commentary: positivity in practice. Am J Epidemiol 2010; 171:674-677discussion 678-681.
46. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009; 23:263-284.
47. Warner L, Newman DR, Austin HD, Kamb ML, Douglas JM Jr, Malotte CK, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol 2004; 159:242-251.
48. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
49. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
50. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol 2010; 39:417-420.
51. Robins JM. A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. J Chronic Dis 1987; 40 (supplement): 139s-161s.
52. Westreich D, Cole SR, Young JG, Palella F, Tien PC, Kingsley L, et al. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med 2012; 31:2000-2009.
53. Taubman SL, Robins JM, Mittleman MA, Hernan MA. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 2009; 38:1599-1611.
54. Hernan MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Safety 2005; 14:477-491.
55. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3:319-336.
56. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-664.
57. Chen PL, Cole SR, Morrison CS. Hormonal contraception and HIV risk: evaluating marginal-structural-model assumptions. Epidemiology 2011; 22:877-878.
58. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
59. Westreich D, Cole SR, Schisterman EF, Platt RW. A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. Stat Med 2012; 31:2098-2109.